Tempus AI, Inc. $TEM Stock Purchased by D.A. Davidson & CO.

Key Points

• D.A. Davidson & CO. increased its Tempus AI stake by 305.3% in the third quarter, ending the period with 21,522 shares valued at about $1.76 million. Institutional investors collectively own 24.22% of the stock.
• Tempus AI reported quarterly revenue of $411.5 million, up 23.1% year over year, and adjusted EPS of $0.07, beating analyst estimates. The company also raised its 2026 revenue outlook to $1.60 billion–$1.605 billion.
• Analyst views are mixed: the consensus rating is Hold, with an average price target of $79.37. Recent insider stock sales and risks including cash burn and acquisition-integration challenges are potential concerns.

D.A. Davidson & CO. boosted its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 305.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,522 shares of the company's stock after buying an additional 16,212 shares during the period. D.A. Davidson & CO.'s holdings in Tempus AI were worth $1,763,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of TEM. Sumitomo Mitsui Trust Group Inc. increased its position in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. grew its stake in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company's stock worth $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Eagle Health Investments LP bought a new position in shares of Tempus AI during the first quarter valued at $11,588,000. Swiss National Bank increased its holdings in shares of Tempus AI by 0.3% during the first quarter. Swiss National Bank now owns 183,500 shares of the company's stock valued at $8,298,000 after acquiring an additional 600 shares in the last quarter. Finally, Aristotle Atlantic Partners LLC purchased a new position in shares of Tempus AI in the 1st quarter worth about $6,179,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Trading Down 0.9%

Shares of NASDAQ:TEM opened at $77.80 on Wednesday. The stock's 50-day simple moving average is $71.04 and its two-hundred day simple moving average is $57.17. The stock has a market capitalization of $14.04 billion, a price-to-earnings ratio of -73.40 and a beta of 3.61. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.16. The company had revenue of $411.54 million for the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 48.29%. The firm's revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.46) earnings per share. Analysts expect that Tempus AI, Inc. will post -1.45 EPS for the current year.

Insider Buying and Selling

In related news, CEO Ryan Fukushima sold 41,095 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the transaction, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. The trade was a 6.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the transaction, the executive vice president owned 146,067 shares of the company's stock, valued at approximately $7,246,383.87. The trade was a 13.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,256,777 shares of company stock valued at $86,356,352 over the last three months. 24.26% of the stock is currently owned by company insiders.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus reported Q3 revenue of $411.5 million, up 23.1% year over year and ahead of expectations. Adjusted earnings of $0.07 per share also beat estimates, which had called for a loss. Tempus AI Surges on Earnings Beat, But Can the Rally Last?
• Positive Sentiment: The company raised its 2026 revenue outlook to $1.60 billion–$1.605 billion and is targeting about $65 million in adjusted EBITDA. Investors are also looking to oncology demand, data partnerships, and reimbursement-related pricing gains as potential growth drivers into 2027. Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
• Positive Sentiment: Several analysts raised price targets after the results: Baird and Cantor Fitzgerald moved to $92, while HC Wainwright raised its target to $85; all maintained positive ratings. Baird analyst recommendations
• Neutral Sentiment: Some coverage cautions that the stock may already reflect much of its recent rally, limiting near-term upside. UBS reiterated a Hold rating with an $80 target. Tempus AI Stock Looks Fully Priced Following Its 26% Run
• Negative Sentiment: Risks include continued cash burn, weaker hereditary-testing performance, and execution challenges related to the proposed Personalis acquisition, which could weigh on results if integration proves difficult. Integration Risks Loom Over Tempus AI’s Proposed Personalis Acquisition

Analyst Upgrades and Downgrades

TEM has been the subject of a number of research analyst reports. Raymond James Financial set a $80.00 target price on Tempus AI in a report on Wednesday, September 2nd. Roth Capital began coverage on Tempus AI in a report on Tuesday, September 8th. They set a "neutral" rating and a $67.00 price target on the stock. TD Cowen reaffirmed a "buy" rating on shares of Tempus AI in a research report on Wednesday, July 15th. Cantor Fitzgerald lifted their price objective on Tempus AI from $80.00 to $92.00 and gave the stock an "overweight" rating in a report on Tuesday. Finally, Stifel Nicolaus decreased their target price on Tempus AI from $60.00 to $50.00 and set a "hold" rating for the company in a research report on Monday, August 3rd. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $79.37.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.